| Bioactivity | REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved[1][2]. |
| Target | Ki: 0.7 μM (leukotriene receptor) |
| Name | REV 5901 |
| CAS | 101910-24-1 |
| Formula | C22H25NO2 |
| Molar Mass | 335.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Inwegen RGV, et, al. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241(1):117-24. [2]. Anderson G, et, al. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol. 1988 Aug;94(4):1115-22. |